DC6
Understanding the genome-wide impact of NAD fluctuations on gene regulation and chromatin structure in cancer
Background: Cancers have an altered metabolism. This altered metabolism can be leveraged for the identification of cancer-specific vulnerabilities. The proof-of-concept has been made for NAD metabolism with synthesis inhibitors showing efficacy in some preclinical cancer models.
Objectives: (1) Analysing the expression of and the dependency on NAD-generating and metabolizing enzymes in cancer samples and cell lines, with a particular focus on enzymes located in the nucleus. (2) Determine genetic and pharmacologic perturbations of nuclear NAD levels in cultured cancer cells. (3) Determine the impact of these perturbations on gene expression and chromatin structure.
Location and research group:
The team of Marcus Buschbeck at the headquarters of the Josep Carreras Leukaemia Research Institute (Badalona, Barcelona, Spain), are looking for a highly motivated highly Doctoral Candidate to work on Project 6 of the MSCA Doctoral Network (DN) HubMol.
The Buschbeck lab performs both basic and applied research. In our basic research, we aim to understand the molecular mechanism by which histone variants link epigenetic regulation to metabolism and nuclear organization. In our translational research, we mine the chromatin regulatory space for combinatorial drug targets that can improve the therapy of blood cancers.